logo-loader
viewVyome Therapeutics Inc.

Vyome Therapeutics expects data from its anti-biotic resistant acne drug end of 2019

Vyome Therapeutics Inc CEO Venkat Nelabhotla sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

Vyome Therapeutics is a clinical stage speciality pharmaceutical company, with platform technologies and a pipeline of drugs for antibiotic-resistant acne and other skin pathogens.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks lift; Canopy Growth names Constellation Brands...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, lifted 1.7% higher at 111.3 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF grew 1.8% to C$9.13, while the OTCQX Cannabis index rose 1.3% to 432.3 points. Buds today are Canopy...

2 hours, 9 minutes ago

2 min read